Monte Rosa Therapeutics annual operating margin
2024
2025
Monte Rosa Therapeutics's operating margin was −43.83% for fiscal 2025.
View full Monte Rosa Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −43.83% | +63.43 pp |
| 2024 | 2024-12-31 | −107.26% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −547.84% | −480.78 pp |
| Q1 2026 | 2026-03-31 | −1,188.46% | −1240.31 pp |
| Q4 2025 | 2025-12-31 | −1,787.67% | −1809.11 pp |
| Q3 2025 | 2025-09-30 | −258.26% | +29.57 pp |
| Q2 2025 | 2025-06-30 | −67.06% | +628.19 pp |
| Q1 2025 | 2025-03-31 | 51.85% | +3336.34 pp |
| Q4 2024 | 2024-12-31 | 21.44% | — |
| Q3 2024 | 2024-09-30 | −287.84% | — |
| Q2 2024 | 2024-06-30 | −695.25% | — |
| Q1 2024 | 2024-03-31 | −3,284.49% | — |
Across the available reported history, Monte Rosa Therapeutics's operating margin increased from −107.26% to −43.83%, a change of +63.43 percentage points. The latest reported quarter, Q2 2026, shows −547.84%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics filings at SEC.gov ↗